C4 Therapeutics Secures Funding to Extend Cash Runway Through 2028, Details $117M Offering

summarizeSummary

C4 Therapeutics' annual report details a successful $116.9 million underwritten offering and warrant issuance in October 2025, extending its cash runway through the end of 2028, significantly de-risking its clinical development programs.

check_boxKey Events

• Extended Cash Runway

  The company projects its cash, cash equivalents, and marketable securities of $297.1 million as of December 31, 2025, will be sufficient to fund operations until the end of 2028, a critical milestone for a clinical-stage biotech.

• Successful Capital Raise

  Net proceeds of $116.9 million were received from an underwritten offering in October 2025, with the potential for an additional $224.7 million if all outstanding Class A and Class B warrants are exercised for cash.

• Increased Authorized Shares

  Stockholders approved an increase in authorized common stock from 150 million to 300 million shares in June 2025, providing flexibility for future capital raises.

• Clinical Pipeline Progress

  Updates include the initiation of the Phase 2 MOMENTUM trial for cemsidomide in February 2026, a planned Phase 1b trial for cemsidomide with elranatamab in Q2 2026, and ongoing Phase 1 clinical development of CFT8919 in Greater China.

auto_awesomeAnalysis

This annual report confirms C4 Therapeutics' strong financial position, with cash and equivalents projected to fund operations until the end of 2028. This significant extension of the cash runway was primarily achieved through a $116.9 million underwritten offering in October 2025, which also included warrants that could provide an additional $224.7 million upon exercise. The company also increased its authorized common stock to 300 million shares in June 2025 to facilitate future capital raises. While the offering was dilutive, it provides critical funding for advancing its clinical pipeline, including cemsidomide in Phase 2 and Phase 1b trials, and CFT8919 in a Phase 1 trial. The report also notes a $10.7 million impairment loss on a right-of-use asset, a minor negative in the context of the overall financial stability. This filing provides the detailed financial context for the cash runway extension previously announced in an 8-K on the same day.